Establishing an Expert Consensus on Key Indicators of the Quality of Life among Breast Cancer Survivors: A Modified Delphi Study
5 de April, 2022
Our three co-founders are among the Women Innovation EU Prize finalists
30 de November, 2022
Best-in-class canceR dIaGnostic cHip for patient sTratification
Project acronym: BRIGHT
Project name: Best-in-class canceR dIaGnostic cHip for patient sTratification.
Project co-funded by the: European Innovation Council
Project number: 190138134
Project Description:Through advanced microengineering and nanotechnology, we have developed a proprietary microfluidic-based liquid biopsy device, the RUBYchip™ (PCT/EP2016/078406). This technology allows for the isolation of all types of CTCs, keeping them viable and enabling the analysis of their phenotypic, genetic and functional characteristics, enabling unprecedented frequent monitoring of cancer progression in a minimally invasive and cost-efficient way. Our chip isolates 70% of the very scarce CTCs from a 7.5mL blood sample of a cancer patient in less than 3 h and without the need of sample pre#processing. This dramatic improvement in the sensitivity compared to competition is enabled by a unique microfilter network embedded in a microfluidic device that separates the CTCs from the healthy cells based on their size and deformability. Furthermore, the RUBYchip enables automation reducing inter-laboratory and inter-user dependence and ensuring reproducible analysis of CTCs.
Start Date: 01/08/2022 End Date: 31/07/2024
Funding Agency: European Innovation Council and SMEs Executive Agency (EISMEA)
Call: HORIZON-EIC-2021-ACCELERATORCHALLENGES-01
Topic: HORIZON-EIC-2021-ACCELERATORCHALLENGES-01-01
Funding Programme: HORIZON EIC
Type of action: Accelerator Blended Finance
Budget Total: 3 568 401.25€ (grant phase)
Maximum grant amount: 2 497 880.88 €
Related Articles
Project acronym: BRIGHT
Project name: Best-in-class canceR dIaGnostic cHip for patient sTratification.
Project co-funded by the: European Innovation Council
Project number: 190138134
Project Description:Through advanced microengineering and nanotechnology, we have developed a proprietary microfluidic-based liquid biopsy device, the RUBYchip™ (PCT/EP2016/078406). This technology allows for the isolation of all types of CTCs, keeping them viable and enabling the analysis of their phenotypic, genetic and functional characteristics, enabling unprecedented frequent monitoring of cancer progression in a minimally invasive and cost-efficient way. Our chip isolates 70% of the very scarce CTCs from a 7.5mL blood sample of a cancer patient in less than 3 h and without the need of sample pre#processing. This dramatic improvement in the sensitivity compared to competition is enabled by a unique microfilter network embedded in a microfluidic device that separates the CTCs from the healthy cells based on their size and deformability. Furthermore, the RUBYchip enables automation reducing inter-laboratory and inter-user dependence and ensuring reproducible analysis of CTCs.
Start Date: 01/08/2022 End Date: 31/07/2024
Funding Agency: European Innovation Council and SMEs Executive Agency (EISMEA)
Call: HORIZON-EIC-2021-ACCELERATORCHALLENGES-01
Topic: HORIZON-EIC-2021-ACCELERATORCHALLENGES-01-01
Funding Programme: HORIZON EIC
Type of action: Accelerator Blended Finance
Budget Total: 3 568 401.25€ (grant phase)
Maximum grant amount: 2 497 880.88 €
